Gao Chen, Cotter Chris, Zhang Tao, Lu Shen-Ning, Lu Hong-Zheng, Su Hong, Li Shi-Zhu, Wang Duo-Quan
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
University of California, San Francisco, California.
Am J Trop Med Hyg. 2024 Dec 24;112(3):593-600. doi: 10.4269/ajtmh.24-0312. Print 2025 Mar 5.
Although China has achieved malaria elimination certification, the risk of malaria transmission reintroduction due to imported malaria remains. We analyzed data on imported malaria cases collected from January 1, 2014 to December 31, 2021, using multivariable logistic regression analysis to identify the factors associated with severe and relapsing malaria. The odds of severe malaria were around 4-fold greater for patients who were initially diagnosed with a nonmalarial illness than for patients initially diagnosed with malaria. The risk of relapse from Plasmodium vivax or Plasmodium ovale varied depending on the regions of Africa where patients resided. Patients residing in western and southern Africa (compared with Central Africa) had a lower relative risk of relapse. In addition, treatment with primaquine provided protection against malaria relapse. Improving the timeliness of treatment of malaria patients could help reduce the severity of illness, and use of primaquine can mitigate the risk of relapse after treatment.
尽管中国已获得消除疟疾认证,但因输入性疟疾导致疟疾传播重新引入的风险依然存在。我们分析了2014年1月1日至2021年12月31日收集的输入性疟疾病例数据,采用多变量逻辑回归分析来确定与重症和复发性疟疾相关的因素。最初被诊断为非疟疾疾病的患者发生重症疟疾的几率比最初被诊断为疟疾的患者高出约4倍。间日疟原虫或卵形疟原虫复发的风险因患者居住的非洲地区而异。居住在非洲西部和南部的患者(与中部非洲相比)复发的相对风险较低。此外,使用伯氨喹治疗可预防疟疾复发。提高疟疾病例治疗的及时性有助于降低疾病的严重程度,使用伯氨喹可降低治疗后复发的风险。